The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Featured:
Table 1. Treatment options for acute GvHD (aGvHD)
aGvHD, acute graft-versus-host disease; ATG, antithymocyte globulin; EBMT, European Society for Blood and Bone Marrow Transplantation; European Leukemia Net; JAK, Janus kinase; MSCs, mesenchymal cells |
|
First-line treatment1,2 |
Recommended second-line treatment 1,2 |
---|---|
First-line treatment for aGvHD is corticosteroids; 60–70% of patients respond to this treatment Systemic treatment ≥ grade II: 2 mg/kg/day methylprednisolone or 2-2.5 mg/kg/day prednisone equivalent |
· Alemtuzumab · Alpha1-antitrypsin · Basiliximab · Cellular therapies, such as MSCs, and regulatory T-cells · Daclizumab · Extracorporeal photopheresis · Fecal microbiota transplantation · JAK inhibitors · Methotrexate · Mycophenolate mofetil · Pentostatin · Rabbit ATG · Sirolimus · Vedolizumab |
Those who do not respond have a 10–30% chance of long-term survival |
Due to the higher risk of infectious complications, immunosuppression-mediated toxicity and incomplete remission of GvHD, these patients still have poor prognoses
|
aGvHD mainly targets the skin, liver and gastrointestinal (GI) tract and is also associated with cytopenia and bone marrow suppression. This can cause life-threatening infections and therefore there is an unmet need to prevent this from occurring.
MSCs are multipotent cells with specific surface antigen expression and an ability to suppress immunological responses, support hematopoiesis and repair tissues. MSCs are found in many tissues including; bone marrow, peripheral blood, umbilical cord blood and adipose tissue. The potential of MSCs to prevent and treat GvHD is a topic of discussion in the field. A recent systematic literature review, covered by the GvHD Hub in July 2019, confirmed the efficacy of MSC treatment to improve complete response (CR) rates and overall survival for chronic GvHD (cGvHD) with a trend towards lower risk of aGVHD.3
Currently, there are no reports in the GvHD field focusing on bone marrow aplasia related with GvHD. Most murine aGvHD models use an irradiation regimen prior to transplant which destroys the bone marrow, making it difficult to study in current models. In order to study bone marrow aplasia related to GvHD, Yukiko Nishi and Akikazu Murakami from the University of the Ryukyus, Okinawa, JP, and colleagues, conducted a study using a murine model with a major histocompatibility complex (MHC)-homozygous donor to heterozygous-recipient, without irradiation or pretreatment with chemotherapy. Their aim was to study the prophylactic potential of adipose-derived-MSCs (AD-MSCs) in GvHD, with a focus on bone marrow aplasia related to aGvHD.
AD-MSCs can be collected via a minimally invasive liposuction procedure, offering a unique advantage over other MSCs. AD-MSCs are also equipotent with a higher immunoregulatory capacity compared to bone marrow-derived MSCs. This model correlates to transfusion-related GvHD, which is different to clinically-occurring GvHD, but allows analysis of AD-MSCs on bone marrow aplasia caused by GvHD.
Table 2. Treatment received by each of the CB6F1 subgroups
Group |
1 x 108 CD57BL/6 splenocytes administered? |
Additional administration |
AD-MSC, adipose-derived mesenchymal stem cell; GvHD, graft-versus-host disease | ||
GvHD |
Yes |
None |
AD-MSC group 1 |
Yes |
1 x 106 AD-MSCs via IV injection on days -1 to 13 |
AD-MSC group 2 |
Yes |
1 x 106 AD-MSCs via IV injection on days -1 to 8 |
CTLA4-Ig |
Yes |
CTL4A-Ig* |
Control |
No |
PBS on days -1 to 13 |
* 200 µg of CTLA 4-Ig IV at the day of GvHD induction and on day 1, and 100 µg administered as an intraperitoneal (IP) injection on days 2–4
AD-MSC characterization
AD-MSC protection against GvHD
AD-MSC protection of organ function
Potential effect of AD-MSC on cell counts in peripheral blood
This is the first study to report results that AD-MSCs are effective against bone marrow aplasia in aGvHD. Administering MHC-mismatched AD-MSCs inhibited the proliferation of donor CD4+ and CD8+ T-cells and increased peripheral blood cell counts indicating the bone marrow of the AD-MSC group contained more hematopoietic stem cells than the GvHD group.
The results support the rationale of using AD-MSCs for ameliorating bone marrow suppression and susceptibility to infections after allo-HSCT in humans.
References